Stifel Trust’s Myriad Genetics MYGN Stock Holding History

Stifel Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-4,000	Closed	-$156K	–	506
2014 Q2	$156K	Hold	4,000	–	–	0.03%	197
2014 Q1	$137K	Hold	4,000	–	–	0.03%	201
2013 Q4	$84K	Hold	4,000	–	–	0.02%	224
2013 Q3	$94K	Sell	4,000 -1,000	-20%	-$28.4K	0.02%	212
2013 Q2	$135K	Buy	+5,000	New	+$145K	0.03%	198

Other funds holding MYGN

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Stifel Trust's MYGN Position: Q3 2014 in Review

Stifel Trust sold out of Myriad Genetics (MYGN) in Q3 2014, closing a stake of 4,000 shares — an estimated $156K sold.

Stifel Trust first reported a position in MYGN in Q2 2013 and held it in 5 quarters. The position peaked at $156K in Q2 2014. 275 funds tracked by Wall St. Rank hold MYGN as of Q3 2014.

Stifel Trust reported no remaining Myriad Genetics position as of Q3 2014 after selling out during the quarter.
Stifel Trust sold 4,000 Myriad Genetics shares in Q3 2014, an estimated $156K.
Stifel Trust first reported a position in Myriad Genetics in Q2 2013 and held it in 5 quarters.
Stifel Trust's Myriad Genetics position peaked at $156K in Q2 2014.
275 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2014.

Based on Stifel Trust's 13F filing for Q3 2014, filed 14 Nov 2014.